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Abstract To develop a suitable formulation with high
entrapment efficiency, etoposide-loaded poly(lactide-co-
glycolide) nanoparticles (NPs) were formulated by single
emulsion-solvent evaporation method by changing different
formulation parameters such as drug loading, choice of
organic solvent and percentage of emulsifier polyvinyl
alcohol. The NPs showed higher entrapment efficiency, ~86%
(with 15% (w/w) drug loading). The physicochemical
parameters revealed smooth topology with size range (240–
320 nm), a negative zeta potential (~19 mV) and in vitro
sustained-release activity (~60% drug release in 40 days).
Greater anti-proliferative activity ~100 times was observed
with NPs (IC50=0.002 μg/ml) than that of native etoposide
(IC50=0.2 μg/ml) in retinoblastoma cell line (Y-79). These
NPs demonstrated greater (G1/S) blocking and decreased
mitochondrial membrane potential as measured by flow
cytometry. There was upregulation of apoptotic gene activity
in NPs than native etoposide, as revealed through microarray
analysis. However, this is the first ever report demonstrating
the intricate modulation of genetic network affected by NPs.
Collectively, these results suggest that etoposide-loaded NPs
could be potentially useful as a novel drug delivery system
for retinoblastoma in the future.
Keywords Retinoblastoma . Ocular drug delivery . PLGA
nanoparticles . Apoptosis . Gene expression
1 Introduction
Retinoblastoma is the most common intraocular malignancy
found during infancy and childhood (Rodriguez-Galindo et al.
2008), and it represents the phenotypic expression of
abnormal or absence of tumour suppressor gene known as
retinoblastoma gene (RB1; Friend et al. 1987). The protein
product of the RB1 gene (the retinoblastoma protein)
regulates a cellular anti-proliferative Rb pathway. The
deregulation of the RB1 gene results in a spectrum of
malignancies (Van Quill et al. 2005). Treatment options for
retinoblastoma include external radiotherapy, episcleral
plaque radiotherapy and cryotherapy (Amendola et al. 2006).
However, these treatments are associated with complications
such as facial deformities, cataract and radiation retinopathy
and with a substantial risk for secondary tumours (Abramson
et al. 1998; Smith and Donaldson 1991). Therefore, systemic
chemotherapy treatment is the only options left for the widely
used treatment of retinoblastoma. However, their clinical use
is limited with systemic toxicity, rapid blood clearance and
drug resistance (Chan et al. 2005; Travis et al. 1999). The
presence of the blood retinal barrier further limits the potential
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of various anticancer drugs. Therefore, ocular drug delivery is
one of the challenging tasks faced by pharmaceutical
scientists because of its critical and pharmacokinetically
specific environment that exists in the eye (Sahoo et al. 2008).
As per the anatomical structure of the eye, the inner and
outer blood retinal barriers separate the retina and vitreous
from the systemic circulation to the vitreous body which
reduces the movement of molecules, further limiting the
potential of various anticancer drugs (Abramson et al.
2003). To increase the therapeutic index, nanotechnology is
one of the potential approaches where cytotoxic drugs are
encapsulated in nanoparticles to augment drug activity by
maximizing drug availability, leading to the reduction of
harmful effects of drug by minimizing drug exposure to
healthy tissues. Harmia et al. (1986) encapsulated pilocarpin in
poly(alkylcyanoacrylate) which are able to improve the
intraocular penetration of drugs. Also, Calvo et al. (1996)
formulated cyclosporine A polyester nanocapsules as a topical
delivery system for improved ocular penetration of drugs.
Similarly, Enríquez de Salamanca et al. (2006) developed
chitosan-based nanocarriers as the potential vehicle for ocular
delivery. However, all of the above studies demonstrated that
these nanoparticles are well tolerated by the ocular surface
tissues. These supportive facts further support the potential
use of nanoparticles to deliver the drugs to the ocular surfaces.
Considering these points, the development of a drug
delivery system is becoming increasingly important in the
treatment of vitreoretinal diseases by facilitating the drug
efficacy and attenuating the adverse effects whilst assisting
their interaction with ocular tissues (Wong et al. 1987).
Nanoparticles are polymeric colloidal particles with size
ranging from 10 to 1,000 nm, in which the therapeutic
agents of interest can be encapsulated or conjugated or
adsorbed to its surface (Sahoo et al. 2008; Misra et al. 2009).
Moreover, polymeric nanoparticles have been evaluated as
ocular drug delivery systems to enhance the absorption of
therapeutic drugs, improve bioavailability, reduce systemic
side effects, and to sustain intraocular drug levels (Hashizoe
et al. 1997; Marchal-Heussler et al. 1993; Zimmer et al.
1995). In addition, polymeric nanoparticles have been shown
to have potential in the treatment of inflammatory external
eye diseases (Diepold et al. 1989). Poly(lactide-co-glycolide)
(PLGA) is a copolymer of poly(D,L-lactide-co-glycolide) and
is an ideal candidate of biodegradable polymers for
formulation into nanoparticles due to its wide medical use,
biocompatibility and safety (Yasukawaa et al. 2004).
Etoposide is an anticancer drug used in the treatment of a
variety of malignancies including malignant lymphomas,
acute myeloid leukemia, lung cancer, Hodgkin’s disease,
non-Hodgkin’s lymphoma, AIDS-related Kaposi’s sarcoma,
gastric cancer, breast cancer and ovarian cancer (Hande
1992; Smit et al. 1989). It acts by inhibiting topoisomerase-
II and activating oxidation/reduction reactions to produce
derivatives that bind directly to DNA and cause DNA
damage (Ashley et al. 1996). Effective cancer therapy for
tumours precisely depends on continuous exposure of the
anticancer agents for a prolonged period of time, which is
not possible due to the short biological half-life (190 min) of
etoposide (Reddy et al. 2006). Etoposide, being a hydrophobic
drug, possesses a dissolution-related absorption problem
because of poor aqueous solubility and bioavailability (Shah
et al. 1995). Snehalatha et al. (2008) have reported the high
significance and advantage of PLGA and PCL nanoparticles
as drug carriers for etoposide with enhanced bioavailability
and reduced etoposide-associated toxicity in rabbits and mice.
Similarly, Yadav and Krutika (2010) have developed a
sustained-release formulation of etoposide for continuous
intravenous administration replacing the conventional therapy.
They have reported that nanoparticles (NPs) remained stable
in terms of both size and drug content for a longer period of
time. Therefore, it is of enormous interest to develop a
formulation which can overcome the solubility and related
bioavailability problems of etoposide as a therapeutic agent
particularly for the treatment of retinoblastoma.
We propose here that the diverse side effects of etopo-
side can be significantly reduced by encapsulating the drug
in the nanoparticulate system. In the present investigation,
etoposide-loaded NPs were formulated to achieve a high
entrapment efficiency of etoposide by varying different
parameters like organic solvent, per cent of drug loading
(w/w) and the amount of polyvinyl alcohol (w/v). We
selected the best suitable formulation with optimum size
range and higher encapsulation efficiency for further
studies. The nanoparticles were characterized in terms of
their particle size, zeta potential, surface morphology and
entrapment efficiency by different techniques. We have
studied the cytotoxicity, cellular uptake (qualitative and
quantitative), induction of apoptosis and modulation of
mitochondrial permeability by these nanoparticles using the
Y-79 cell line, and these results were compared with native
etoposide. Moreover, the NPs were further evaluated for the
regulation of different apoptotic gene activities in the
retinoblastoma cell line by microarray technique.
2 Materials and methods
2.1 Materials
Poly(D,L-lactide-co-glycolide) (copolymer ratio 50:50, viscosity
0.55–0.75) was purchased from Birmingham Polymers Inc.
(Birmingham, USA); propidium iodide (PI) from MP,
Biomedicals, Inc. (Germany); AnnexinV-FITC from
Biosciences, Pharmigen; Pierce BCA Protein Assay Kit
(Rockford, IL, USA); and uranyl acetate from Electron
Microscopy Sciences (Hatfield, PA, USA). Polyvinyl
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alcohol (PVA, average Mw 31,000–50,000), etoposide, 6-
coumarin, Tween 80 (polyoxyethylene sorbitan monooleate),
Igepal CA-630, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrasodium bromide) reagent and different salts
were purchased from Sigma-Aldrich Co. (St. Louis, MO,
USA). All other chemicals used in this study are of analytical
grade from E Merck (India). Uranyl acetatae was from
Electron Microscopy Services, Ft. (Washington, PA, USA)
and carbon-coated copper TEM grid (150-mesh) from Ted
Pella Inc. (Rrodding, CA, USA).
2.2 Preparation of etoposide-loaded nanoparticles
The NPs were prepared by single emulsion-solvent evap-
oration technique (Sahoo et al. 2004a). Briefly, 90 mg of
PLGA was dissolved in 3 ml of chloroform or dichloro-
methane. To the above mixture, either 10% or 15% (w/w)
etoposide was added and emulsified with 12 ml of either
2% or 5% (w/v) aqueous solution of PVA. The emulsifica-
tion was carried out using a microtip probe sonicator (VC
505, Vibracell Sonics, Newton, USA) at 39 W of energy for
2 min in an ice bath and stirred with a magnetic stirrer
overnight to evaporate the organic solvent. The NPs were
recovered by ultracentrifugation at 40,000 rpm for 20 min
at 4°C (Sorvall Ultraspeed Centrifuge, Kendro, USA),
followed by washing twice with double distilled water.
The obtained particles were resuspended in double distilled
water and lyophilized (−80°C and <10-μm mercury
pressure, LYPHLOCK 12, Labconco, Kansas City, MO,
USA) for 48 h. Lyophilization is required for longer storage
and stability of these nanoparticles which can be stored at
4°C for further experiments (Lemoine et al. 1996). To study
the cellular uptake of NPs, 6-coumarin was used as a model
fluorescent probe. To formulate 6-coumarin-loaded nano-
particles, 50 μl (1 mg/ml) of dye (dissolved in methanolic/
chloroform, 12.5:87.5, v/v) was added to the polymer
solution prior to emulsification instead of etoposide
formulation.
2.3 Determination of encapsulation efficiency by RP-HPLC
To estimate the amount of drug entrapped inside the NPs
drug content, 10 mg of etoposide nanoparticles was
dissolved in 10 ml of methanol, sonicated in an ice bath for
1 min at 39 W (VC 505, Vibracell Sonics) and centrifuged at
13,800 rpm for 10 min at 25°C (Sigma1-15K, Germany). The
supernatant was estimated by the reverse phase isocratic mode
of HPLC with slight modification (Shirazi et al. 2001):
Agilent 1100 (Agilent Technologies, Waldbronn Analytical
Division, Germany), featured with C18 column (Zorbax
Eclipse XDB-C18,150×4.6 mm, i.d), quaternary pump
(model no. G1311A), thermostart (model no. G1316A) and
a diode array detector (model G 1315A). Twenty microlitres
of the sample was injected manually in the injection port and
analysed with a flow rate 1 ml/min at 60°C with UV
detection at 220 nm using the mobile phase of methanol/
water (45:55, v/v). The standard curve of etoposide was
prepared under identical condition. The encapsulation
efficiency (%) was determined as the percentage of drug
entrapped in nanoparticles with respect to the initial
amount of drug added in the formulation (Sahoo et al.
2004a).
2.4 Physicochemical characterization of nanoparticles
Particle size, size distribution and zeta potential of the
etoposide nanoparticles were determined by photon corre-
lation spectroscopy and laser Doppler anemometry, respec-
tively, using Zetasizer (Nano ZS, ZEN 3600, Malvern
Instrument, UK) with a red laser of wave length λ0=633nm
(He–Ne, 4.0 Mw). For the above measurement, the
lyophilized nanoparticles were suspended in double distilled
water and sonicated to get a homogenous suspension. The
acquired suspension was examined for mean diameter, size
distribution, polydispersity and zeta potential. Scanning
electron microscopy (Hitachi S-3400N, USA) was used to
determine the shape and surface morphology of the nano-
particles. The powdered particles were gold-coated and
vacuum-dried before scanning electron microscopy (SEM).
For the transmission electron microscopy (TEM, Philips
CM-10, FEI Inc., Hillsboro, OR, USA), a drop of diluted
and sonicated solution of nanoparticle was negatively
stained with 1% uranyl acetate for 10 min, placed in
carbon-coated copper TEM grid and air-dried before
TEM. Fourier transform infrared spectroscopy (Perkin
Elmer model Spectrum1, USA) measurement was done
to determine the possible chemical interaction between
the drug and the polymer. The samples (native etoposide,
void NPs and NPs) were crushed individually with KBr
to get the pellets by applying a pressure of 300 kg/cm2,
and the spectra scanned were obtained in the range
between 4,000 and 500 cm−1 using IR solution software
(version 1.10). Differential scanning calorimetry (DSC
821, Mettler Toledo, Switzerland) technique was imple-
mented to determine the physical state of the encapsulated
etoposide in nanoparticles. Each sample (native etoposide,
void nanoparticles and etoposide nanoparticles) was
sealed separately in a standard aluminium pan, purged
with pure dry nitrogen with a flow rate of 10 ml/min, at
10°C/min, and heat flow recorded from 0°C to 350°C.
2.5 In vitro release of etoposide from nanoparticles
The release of drugs from nanoparticles was carried out in
phosphate-buffered saline (PBS, 0.01 M, pH 7.4, containing
0.1% (w/v) of Tween 80) in triplicates (Sahoo et al. 2004a).
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In brief, 10 mg of nanoparticles was dispersed in 3 ml of
PBS, sonicated (30 s) and equally distributed into three
tubes. Then, the tubes were placed in an orbital shaker bath
(Wadegati Lab Equip, India) maintained at 37°C and with
horizontal rotation at 150 rpm. At predetermined time
intervals, the tubes were taken out of the shaker and
centrifuged at 13,800 rpm for 10 min at 4°C (Sigma
Microcentrifuge 1-15K, Germany). The entire supernatant
was collected for further analysis. The residue pellet was
resuspended with fresh PBS and placed back into the shaker
to continue the release measurement. The collected super-
natants were lyophilized for 48 h, dissolved in methanol for
the dissolution of the drug and centrifuged at 13,800 rpm for
10 min. The obtained supernatant was subjected to RP-
HPLC analysis to determine the amount of etoposide
released as described above.
2.6 Quantitative cellular uptake of nanoparticles
Cellular uptake efficiency of cells was studied using 6-
coumarin-loaded nanoparticles. For this, the cells were
seeded at 5×104 per well density in 24-well plates
(Corning, NY, USA) and left 24 h for attachment;
thereafter, cells incubated for 2 h with 300 μg/ml of 6-
coumarin-loaded nanoparticles and equivalent concentra-
tion of native 6-coumarin. After the incubation period, the
cells were washed thrice with PBS (0.1 M, pH 7.4) and
lysed by incubating them with 0.1 ml of 1× cell lysis
reagent (Igepal CA-630, Sigma-Aldrich) for 30 min at 37°C.
From which, 5 μl was taken out for the cell protein estimation
using the Pierce BCA protein assay. The remaining cell lysate
was lyophilized. The dye from the lyophilized nanoparticles
was extracted by dissolving each sample with 1 ml of
methanol/chloroform (12.7:87.5, v/v) solution and kept in a
shaker at 37°C for 48 h at 150 rpm/min in an orbit shaking
incubator (Wadegati Labequip, India) for the complete
removal of the dye from the NPs. The samples were then
centrifuged at 13,800 rpm for 10 min at 4°C and the
supernatants collected. Fluorescence intensity of the super-
natants was measured by a fluorescent spectrophotometer
(Synergy HT, BioTek® Instruments, Inc., Winooski, VT,
USA) at λex = 450 nm and λem = 490 nm. A standard plot of
6-coumarin nanoparticles (2–50 μg/ml) was constructed in a
similar way to determine the amount of nanoparticles in the
cell lysate. The uptake of nanoparticles by cells was calculated
from the standard plot and expressed as the amount of
nanoparticles (μg) taken per milligram cell protein.
2.7 Cytotoxicity assay
A comparison of the cytotoxic activity of NPs and native
etoposide was performed using the MTT assay as described
earlier (Sahoo et al. 2004b). Y-79 cells were plated in 96-
well plates (Corning) at a density of 5,000 cells/well
incubated for 24 h for cell adherence. A stock solution of
etoposide was prepared in DMSO (1 mg/ml) and stored
at −70°C. Different aliquots of the stock solution after
suitable dilution were added to the culture medium to
achieve the desired drug concentration. The concentration
of DMSO in the medium was kept 0.1% so that it has no
effect on the cell proliferation. Cells were incubated with
different concentrations of etoposide either as solution or
encapsulated in NPs. Medium and void nanoparticles
(without drug) served as respective controls. The medium
was changed on every alternate day and no further dose of
the drug was added. The cell viability was determined at the
fifth day following drug treatment using the MTT reagent.
Ten microlitres of the MTT solution was added to each well
and incubated at 37°C for 3 h in a cell culture incubator.
The medium was removed and replaced with 100 μl of
DMSO to dissolve formazan crystals; absorbance was read
at 540 nm using a microplate reader (Synergy HT, BioTek®
Instruments, Inc.). The anti-proliferative effects of different
treatments were calculated as a percentage of cell growth
with respect to the respective controls. IC50, the concentra-
tion of the drug at which 50% cell growth is inhibited, was
calculated by the curve fitting of the cell viability data using
Prism 4.0 (GraphPad, San Diego, CA, USA).
2.8 Cell cycle analysis
The distribution of DNA in the cell cycle was studied by
flow cytometry. Cell cycle analysis of native etoposide and
etoposide-loaded nanoparticles was done with slight mod-
ification (Noh et al. 2004). Briefly, 5×105 cells/5 ml were
seeded in T-25 flask (Corning) and incubated overnight for
better attachment. The cells were exposed to a particular
concentration (0.0005 μg/ml) of drug in solution, drug-
loaded nanoparticles in RPMI medium, and incubated for 48
and 120 h. Void nanoparticle-treated cells and untreated cells
were used as respective controls. The cells were collected and
washed with PBS (0.1 M, pH 7.4) twice and resuspended in
hypotonic propidium iodide solution (10 μg of propidium
iodide, 10 μg of RNase A and 0.5% ”Tween 20 in 1 ml of
PBS) for 1 h at room temperature and kept in the dark at 4°C
before analysis. Cell cycle distribution was determined by
analysing 10,000 cells using FACScan flow cytometer and
Cell Quest software Caliber (Becton-Dickinson, San Jose,
CA, USA). All experiments were performed in triplicate.
2.9 Mitochondrial membrane permeability study
Mitochondrial membrane depolarization study was done
using flow cytometry (Raffaella et al. 2005). Briefly, 5×105
cells per well were seeded and incubated overnight. The
cells were exposed to a particular concentration (0.0005 μg/ml)
24 M. Mitra et al.
of native etoposide and etoposide-loaded nanoparticles for
5 days. The medium was changed in every alternate day. Cells
were stained with the cationic dye 5,5,6,6 tetrachloro-1,1,3,3-
tetraethylbenzimidazol-carbocyanine iodide (JC-1, 3 μg/ml)
for 10 min at 37°C, which exhibits potential-dependent
accumulation in mitochondria. The cells were washed with
PBS (0.1 M, pH 7.4) twice and analysed using FACScan
flow cytometer and Cell Quest software Caliber (Becton-
Dickinson). All experiments were performed in triplicate.
2.10 Assessment of apoptosis
Annexin V-FITC staining was used for the assessment of
apoptosis. This assay is based on the observation that soon
after the initiation of apoptosis, phosphotidylserine (PS)
translocates from the inner face of the plasma membrane to
the cell surface. The translocated PS can thus be easily
detected by staining with a FITC conjugate of Annexin V, a
protein that has a strong natural affinity for PS (Martin et al.
1995). In our experiments, 1×106 cells/well were cultured
on six-well plates (Corning) in 3 ml medium; 24 h post-
seeding, they were treated with two different concentrations
(0.0005 and 0.005 μg/ml) of the native drug and etoposide-
loaded nanoparticles, and 5 days after treatment, the cells
were collected from the wells, centrifuged, washed thrice
with PBS (0.01 M, pH 7.4) and incubated for 15 min in the
dark in 100 μl of binding buffer containing 2 μg/ml
Annexin V-FITC (BDBiosciences Pharmingen) and 10μg/ml
of the vital dye, propidium iodide (MP Biomedicals, Inc.,
Germany). Thereafter, the cell suspension was placed on a
glass slide, covered with a glass coverslip and photographed
using a fluorescence microscope (Nikon Fluorescence, Nikon,
Japan) equipped with blue, red and green filter attachment.
The apoptotic index was obtained by dividing the number of
apoptotic cells by the total number of cells, multiplied by 100
(Rödel et al. 2003). A minimum of 1,000 cells were counted
using an image analyzer.
2.11 DNA fragmentation studies by gel electrophoresis
DNA fragmentation into oligonucleosomal ladder is a
characteristic of apoptosis. To study this, 1×106 cells per
well were seeded in six-well plate (Corning) and after 24 h
were then treated with two different concentrations (0.0005
and 0.005 μg/ml) of the drug either as a solution or
encapsulated in nanoparticles. Medium and void nano-
particles served as respective controls. After 5 days of post-
treatment, cells were collected, washed and centrifuged at
2,500 rpm for 5 min. The cell pellet was lysed with 0.1 ml
of 1× cell lysis buffer (Igepal CA-630, Sigma-Aldrich) and
incubated for 30 min at 37°C; after, 2 μl of 10 μg/ml
RNase was added and incubated for a further 1 h. The
obtained cell lysate samples of 20 μl/well were subsequently
run at 120 Von a 1% (w/v) agarose gel containing 0.1 mg/ml
ethidium bromide. Gels were examined on an ultraviolet
light source and photographed.
2.12 Statistical analysis
Statistical analyses were performed using a Student’s t test
of the software, and the differences were considered
significant for p values of <0.05* and <0.005**.
3 Results and discussion
3.1 Physicochemical characterization of nanoparticles
NPs were prepared by single emulsion-solvent evaporation
technique. The particle size (hydrodynamic diameter) of
nanoparticles observed by dynamic laser light scattering
(DLS) technique revealed their size in the range of 240–
320 nm (Table 1). Figure 1a depicts the size of the NPs
observed by the DLS. The smooth and rounded shape
topology of the nanoparticles was confirmed by SEM
(Fig. 2b) and internal diameter of ~200 nm, as observed
from TEM (Fig. 1c). The particle size measurement by DLS
is higher than that of TEM measurement because DLS
measures the apparent size, including the hydrodynamic
layers formed due to hydrophilic coating around the
nanoparticles, thus leading to overestimation of the size
(Acharya and Sahoo 2009) as particle size is an important
parameter and has a direct relevance with the stability,
cellular uptake, drug release and biodistribution (Panyam
et al. 2004). Concerning this, we have studied the influence
of different formulation parameters such as the organic
solvent (dichloromethane or chloroform) and the amount of
emulsifying agent (e.g. PVA) on particle size NPs, as
depicted in Table 1. The results demonstrated that the
particle size was larger in chloroform than dichloromethane
irrespective of the amount of drug loading (Table 1). The
slight decrease in particle size using dichloromethane as
solvent may be due to the miscibility of dichloromethane
with the aqueous phase used in formulation than that of
chloroform as dichloromethane is soluble in ~50 parts of
water, whereas chloroform is soluble in ~200 parts of water
(Table 2). The acquired data clearly indicated the influence
of the physical properties of the organic solvent in the
physicochemical properties of the nanoparticles due to the
fact that PVA partitioned into the polymeric phase contain-
ing an organic solvent that is more miscible with the
aqueous phase, forming smaller emulsion droplets; as a
result, there was a decrease in nanoparticle size in the case
of dichloromethane-mediated formulation (Sahoo et al.
2002). Furthermore, the concentration of PVA also influ-
enced the size of nanoparticles (Sahoo et al. 2002).
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Therefore, we studied the effects of different PVA concen-
trations (2% and 5%) in the external aqueous phase on the
particle size. With the increase of PVA concentration in the
external aqueous phase, the mean nanoparticle size also
decreased irrespective of the use of organic solvent and
percentage of drug loading (Table 1). This might be due to
the more number of PVA molecules oriented at the organic
solvent/water interface to reduce the interfacial tension
during emulsification, which prevents nanoparticle aggre-
gation during the process of organic solvent evaporation
(Sahoo et al. 2002). The formulated NPs showed negative
surface charge attributed to the presence of ionized
carboxylic groups on the surface of the nanoparticles in
the range of −14 to −25 mV, as depicted in Table 1.
Apart from the smaller size, the successful implementation
of nanoparticles as drug delivery vehicles requires a higher
drug loading efficiency. Therefore, we have used 10% or 15%
(w/w) drug loading corresponding to the polymer weight
(Table 1). We achieved higher encapsulation efficiency in the
case of 15% (w/w) drug loading irrespective of the organic
solvent and concentration of emulsifier. An increased
encapsulation efficiency up to ~86% was achieved using
chloroform as organic solvent, whereas using dichloro-
methane, the encapsulation efficiency reached up to ~72%.
The slightly hydrophilic nature of dichloromethane leads to a
slightly lower entrapment efficiency with smaller particle
size, whereas the less hydrophilic nature of chloroform leads
to higher entrapment efficiency with a slightly bigger particle
size. This could happen probably due to more accommoda-
tion of drug molecule in the polymeric surface due to drug–
polymer interaction (Panyam and Labhasetwar 2004).
Besides, the polarity behaviour of the organic solvent
(Table 2) also might have affected the entrapment efficiency
during the nanoparticle formulation. Therefore, in our
formulation, we established chloroform to be a more suitable
solvent than dichloromethane for the encapsulation of the
hydrophobic drug etoposide (Table 1).
3.2 FT-IR analysis
Fourier transform infrared spectroscopy (FT-IR) spectral
analysis was exercised to determine any possible chemical
interaction (formation of chemical bonds) that occurred in
the polymer due to the addition of drug during the synthesis
process (Misra et al. 2009; Vandana 2009). Figure 2
depicted the FT-IR spectra of void nanoparticles, native
etoposide and NPs. The spectra of NPs showed the
presence of bands similar to void NPs along with some
extra bands due to the drug. The vibrational spectral
analysis of native etoposide illustrated characteristic bands
due to different functional groups such as 3,450, 2,892,
1,769, 1,615,1,459, 1,390 and 1,161 cm−1, corresponding
to OH, –CH2 stretching, lactone group, aromatic groups, –
Table 1 Comparative analysis of encapsulation efficiency, size and zeta potential of etoposide-loaded nanoparticles
PVA (%) Drug loading (%, w/w) Organic solvent Encapsulation efficiency (%)a Mean diameter (nm)b Zeta potential (mV)c
2 10 CHCl3 61 316±1.5 −14±0.9
– 15 – 80 322±1.1 −14±0.9
– 10 CH2Cl2 41 299±1.1 −17±1.1
– 15 – 55 305±0.9 −19±1.2
5 10 CHCl3 60 267±1.2 −20±1.3
– 15 – 86 270±1.0 −19±1.6
– 10 CH2Cl2 56 247±1.2 −24±1.8
– 15 – 72 251±1.1 −22±1.2
a Encapsulation efficiency of the etoposide-loaded nanoparticles
b Size (in nm) as measured by dynamic laser scattering method
c Zeta potential (in mV) as measured by zetasizer
Fig. 1 aMeasurement of size distribution of NPs through particle size
analyzer. b SEM of NPs. c TEM of NPs
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OH, –C–O from –OCH3 and AROH functional groups,
respectively. Similar types of bands were also observed
earlier (Jasti et al. 1995). However, the vibrational spectral
peaks of drugs at 3,450, 2,892 and 1,769 cm−1 are slightly
displaced to 3,434, 2,998 and 1,761 cm−1 in NPs due to
some minor chemical interaction between etoposide and the
PLGA matrix. Moreover, the band appearing at 1,769 cm−1
in native etoposide also appeared in NPs with increased
intensity, indicating the presence of negligible chemical
interaction with the polymer. However, such chemical
interaction has no significant effect on the in vitro release
profile of drug. Similar chemical integrity and chemical
stability of doxycycline drug inside the nanoparticles were
also studied through FT-IR analysis (Misra et al. 2009).
3.3 DSC studies
DSC study was performed to determine the nature of the
encapsulated drug inside the NPs. The DSC results revealed
the amorphous nature of the encapsulated drug. Through
DSC analysis, the endothermic peak of the PLGA polymer
was observed at 54°C as PLGA exhibited a glass transition
temperature (Tg) at ~54°C. The endothermic peak of native
etoposide was found approximately at 189°C (Fig. 3). This
characteristic peak was not observed in NPs, which
indicated that the encapsulated drug in nanoparticles is in
amorphous or disordered-crystalline phase in the polymer
matrix, resulting in the molecular dispersion of the drug
inside the nanoparticles (Misra et al. 2009).
3.4 In vitro release profile of nanoparticles
The release profile of etoposide from the nanoparticles was
studied in vitro using PBS (0.01 M, pH 7.4). A typical two-
phase release profile was observed, as depicted in Fig. 4
which demonstrated a relatively rapid release in the early
time point (~ 28% of the entrapped etoposide release in
72 h) followed by sustained and slow release over a
Table 2 Physical properties of the solvents
Solvent Boiling point (°C) Melting point (°C) Solubility in water at 25°C Interfacial tension (dyne/cm) Viscosity (Cp)
Dichloromethane 39.75 −95 1 in 50 28.3 0.44
Chloroform 61–62 −63.5 1 in 200 32.8 0.57
Data as taken from Sahoo et al. (2002)
Fig. 2 FT-IR spectra of void nanoparticles (i), native etoposide (ii) and etoposide-loaded nanoparticles (iii)
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prolonged time period (~60% of the drug released in
6 weeks). The release of a drug from the polymeric
nanoparticles is a rather complicated process (Reddy et al.
2006; Panyam and Labhasetwar 2004). The initial release
of etoposide might be due to the rapid release of drugs
deposited on the surface along with the formation of water
channels in nanoparticles. Since the degradation of PLGA
is slow, at a later stage, the release of etoposide from the
nanoparticles primarily depends on the drug diffusion and
degradation of the polymer matrix itself (Panyam and
Labhasetwar 2003).
3.5 Cellular uptake of native 6-coumarin and 6-coumarin-
loaded nanoparticles
The photoluminescent behaviour of 6-coumarin has been
recognized as a useful tool for the cellular uptake study of
non-fluorescent drug molecules through fluorescence/
confocal microscopy (Davda and Labhasetwar 2002).
The intracellular uptake of 6-coumarin-loaded nanoparticles
and native 6-coumarin was examined in Y-79 cells quantita-
tively by fluorescence spectroscopy. Cellular uptake studies
illustrated that 6-coumarin-loaded nanoparticles were
internalized more in comparison with native 6-coumarin
(Fig. 5a). It was observed that the cellular uptake of
6-coumarin-loaded nanoparticles were internalized approxi-
mately sevenfold higher as compared with native 6-coumarin.
This might be attributed to the fact that the entry of the
dye-loaded nanoparticles into the cells is via endocytosis
as compared with the entry of native 6-coumarin by a
passive diffusion mechanism (Sahoo and Labhasetwar
2005). The studies of Qaddoumi et al. (2003) revealed that
the uptake of the PLGA nanoparticles in primary culture
of rabbit conjuctival epithelial cells occurred through
endocytosis. Other independent observation of the endocytic
uptake of the nanoparticles was also reported (Acharya and
Sahoo 2009). The higher cellular uptake of the nano-
particulate formulation versus native 6-coumarin could be
explained on the basis of the increased cellular accumulation
of the encapsulated dyes. The endocytic uptake of the
colloidal nanoparticles was also revealed by independent
studies (Enríquez de Salamanca et al. 2006; Douglas et al.
2008). Our studies evidently demonstrated the significance
of the use of nanoparticles as a potential system compared to
the free drug due to the enhanced drug retention and greater
intracellular uptake for improved therapeutic efficacy.
We have studied the intracellular uptake of nanoparticles
by confocal microscopy. The cells exposed to nanoparticles
demonstrated increased fluorescence activity. Maximum
fluorescence activity was observed in cells exposed to
6-coumarin-loaded nanoparticles, which indicated that
nanoparticles were internalized more by the cells than
native 6-coumarin (Fig. 5b). The fluorescence intensity of
native 6-coumarin decreased with increased incubation
time, i.e. 2, 24, 48 and 120 h. But in the case of 6-
coumarin-loaded nanoparticles, the fluorescence intensity
increased with increased time of incubation, signifying
that the nanoparticulate formulation might act as an
intracellular depository to maintain a sustained release of
the dye from nanoparticles.
3.6 Cytotoxicity studies of native drug and nanoparticles
The therapeutic efficacy of drug-loaded nanoparticles
would mostly depend on nanoparticle uptake, their
intracellular distribution and, more notably, on the dose
of the drug that is released from the internalized
nanoparticles inside the cell (Acharya and Sahoo 2009).
To investigate the induction of therapeutic efficiency of
the formulations, Y-79 cells were treated with native
etoposide, void nanoparticles (without drug) and NPs at
Fig. 3 Differential scanning calorimetry thermogram curves of native
etoposide (i), void nanoparticles (ii) and NPs (iii)
Fig. 4 In vitro release profile of etoposide from nanoparticles in PBS
(0.1 M, pH 7). Data are as the mean ± SEM (n=3)
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different concentrations for 5 days, and cell proliferation
was measured by a standard MTT colorimetric assay. In
vitro cytotoxicity studies exhibited the void nanoparticles
to be nontoxic, which is similar to the medium with cells
serving as control (data not shown), whereas the NPs
demonstrated higher anti-proliferative activity than native
etoposide (Fig. 6). Observation from IC50 values indicated
the 100 times superior anti-proliferating efficiency for NPs
(0.002 μg/ml) than that of native drug (0.21 μg/ml). The
higher anti-proliferative activity could be attributed to the
higher uptake of the nanoparticulate formulation, which
leads to the accumulation and sustained release of the
drug for a prolonged period of time at the site of action.
Similar reports were observed with podophyllotoxin-
loaded nanoparticles (etoposide is a derivative product
of podophyllotoxin) on HeLa cells. Podophyllotoxin-
loaded solid lipid nanoparticles (PDP-SLN) were formulated
and its anti-proliferative activity was observed with MTT
assay in HeLa cells. PDP-SLN showed effective anti-
proliferation activity with lower a IC50 value of 0.2 μm/l than
native podophyllotoxin, IC50 value around 1.3 μm/l (Shi
et al. 2008). This might probably be the reason why the
drug-loaded nanoparticles are internalized more into the cells
and escape the multiple drug resistance barriers (Shi et al.
2008; Garcion et al. 2006). Apart from that, the polymeric
envelope protects and prevents the drug degradation from the
Fig. 5 a Cellular uptake
of native 6-coumarin and 6-
coumarin-loaded nanoparticles
in Y-79 cells at 37°C. Data are
represented as the mean ± SEM
(n=6). **p<0.005, 6-coumarin-
loaded nanoparticles versus na-
tive 6-coumarin. b Confocal
fluorescence images highlight-
ing time-dependant intracellular
uptake of native 6-coumarin and
6-coumarin-loaded nanopar-
ticles. Scale bar, 30 mm
Fig. 6 Dose-dependent cytotoxic effect of etoposide in solution and
in NPs. Different concentrations of etoposide either as solution (black
square) or encapsulated in nanoparticles (black circle) were added to
the wells. The medium was changed on the second day and fourth day
with no further additional dose of drug. The extent of growth
inhibition was measured on the fifth day by the MTT assay. The
nanoparticles (without drug) or medium acts as respective controls.
The percentage of survival was determined by standardizing the
absorbance of controls to 100%. Data as ±SEM (n=6). **p<0.005
NPs versus etoposide solution
Toxicogenomics of nanoparticulate delivery of etoposide 29
harsh internal environment, hence providing the concentra-
tion gradient for influxing of the drug in the cell. Whereas
the native drug in the form of solution is vulnerable to all
such conditions and degrades early as a result, it is not able
to show the required anti-proliferative effect. Therefore, the
higher efficacy of etoposide in NPs than the native etoposide
in solution is due to the continuous exposure and sustained
release of the drug for a prolonged period of time.
3.7 Cell cycle analysis of native drug and nanoparticles
Different drugs are known to have a range of pharmacological
actions, including their effect on genes controlling the cell
cycle and stimulation of pro- and antiapoptotic genes, and
inhibition of secretion of various growth factors and cytokine-
promoting inflammation (Panyam and Labhasetwar 2004).
Etoposide inhibits cell growth and proliferation primarily
through its effect on the cell cycle arrest and initiation of
apoptosis (Shah et al. 1995). Void nanoparticle had no effect
on cell cycle progression as compared to native cells and
thus is nontoxic in nature. Figure 7a, b illustrated that
incubating cells with NPs up to 48 h, maximum (61%) G1/S
blocking occurred as compared with native etoposide (52%).
The hypodiploid peak (sub-G1) appearing before the G1
phase on the histogram is called the apoptotic peak (Misra
and Sahoo 2010), which indicates reduced DNA content in
apoptotic cells in flow cytometry analysis. After 120 h of
incubation, maximum percentage of apoptotic cells (12%)
was found in the sub-G1 phase, which resulted in lesser
proportion of G1/S (57%) blocking as compared with 48 h of
incubation, whereas native etoposide showed comparatively
lower apoptotic cells (9%) and G1/S blocking (46%). These
results represented that with 48 h of incubation with NPs,
which first leads to cell cycle inhibition and afterwards with
increased time of incubation, the nanoparticles supplemented
sustained release of drugs, which resulted in apoptosis. The
above results can be easily corroborated with our 120 h of
DNA fragmentation study.
3.8 Assessment of apoptosis by mitochondrial permeability/
Annexin V-FITC and DNA fragmentation method
Changes in mitochondrial membrane potential were analysed
using a flow cytometer by using a mitochondria-selective dye,
JC-1. The cationic dye JC-1 exhibits potential-dependent
accumulation in the mitochondria, indicated by a fluorescence
shift from green (~529 nm) to orange (~590 nm), due to the
concentration-dependent intramitochondrial formation of
Fig. 7 Effect of native etoposide and NP treatments on cell cycle
distribution in Y-79 cells. Cell cycle distribution was determined by
analysing 10,000 ungated cells using FACScan flow cytometer.
Content of DNA is represented on the x-axis; number of cells counted
is represented on the y-axis (n ¼ 3). a Cells incubated for 48 h. b Cells
incubated for 120 h
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orange fluorescent oligomers. As a consequence, the
changes in the mitochondrial membrane potential (Δψm)
can be optically measured by the orange/green fluores-
cence intensity ratio occurring during the process of
apoptosis. During the apoptotic event, firstly, the mito-
chondria provide energy in the form of ATP, requisite for
cells to die by the apoptotic pathway, and eventually
release proapoptotic proteins into the cytosol to trigger
the downstream apoptotic signalling pathways. The flow
cytometry analysis (Fig. 8a, b) showed that NPs
(0.0005 μg/ml) induced a decreased in dye uptake,
indicating loss of Δψm. The mitochondrial membrane
potential decreased by 4.4% in 48 h and 8.8% in 120 h,
thus demonstrating that NPs disturbed the mitochondrial
function, leading to the disruption of Δψm in greater
proportion than native etoposide (3.3% in 48 h and 4.6%
in 120 h) and leading towards the apoptosis event.
Apoptosis is the intrinsic death programme of a cell which
plays a crucial role in the regulation of tissue homeostasis,
characterized by chromatin condensation, membrane bleb-
bing and cell fragmentation (Cohen 1993). Apoptosis is
considered to be one of the mechanisms by which
etoposide induces tumour regression in the retinoblastoma
cell lines (Martin et al. 1995). To analyse the event,
Annexin V-FITC assay was performed for the evaluation
of initiation of apoptosis in cells. Annexin V is a 35- to
36-kDa phospholipid-binding protein that has high affinity
to PS. In the early apoptotic event, the membrane
phospholipid PS is translocated from the inner face of
the plasma membrane to the cell surface and exposed to
the external cellular environment to which Annexin V-
FITC binds. The use of the vital dye, PI, can distinguish
the apoptotic cells with intact membranes from lysed
necrotic cells. Therefore, the cells showed green staining
(Annexin V-FITC) on the plasma membrane of early
apoptotic cells, whereas the cells that have lost membrane
integrity showed red staining (PI) throughout the nuclei
and a halo of green staining (AnnexinV-FITC) on the
plasma membrane. Cells that stained negative for both
Annexin V-FITC and PI are alive and not undergoing
measurable apoptosis. Our NP-treated cells demonstrated a
significant increase of apoptotic index, ~46% (0.0005 μg/ml)
and ~53.15% (0.005 μg/ml), as evident from the red
fluorescence signal, whereas the native etoposide-treated cells
showed early apoptotic index, ~11.56% (0.0005 μg/ml)
and ~19.28% (0.005 μg/ml), as illustrated by the green
fluorescence signal (Fig. 9a). Our results demonstrated
that at low concentration, the nanoparticulate formulation
induced more number of apoptotic and necrotic cells than
that of native drug. This could be due to the higher
internalization of the drug-loaded nanoparticles inside the
cells, which leads to the combined effect of apoptosis and
necrosis events. Since cell death is the eventual outcome
of cells undergoing apoptosis, cells in the late stages of
apoptosis will have a damaged membrane which stained
positive for PI as well as for Annexin V-FITC.
Apoptosis was also further confirmed by DNA fragmen-
tation, as DNA fragmentation into the oligonucleosomal
ladder is the characteristic of apoptosis, and the percentage
of DNA fragmentation in cultured cells exhibited a direct
correlation with the percentage of apoptotic DNA (Ioannou
and Chen 1996). The results demonstrated that the Y-79
cells treated with different concentrations of NPs (0.0005
and 0.005 μg/ml) underwent more DNA fragmentation as
compared with native etoposide (Fig. 9b). As our formu-
lation showed higher cytotoxic effect than native etoposide,
Fig. 8 Involvement of
mitochondria in apoptosis
induced by etoposide and NPs
(0.0005 μg/ml) in Y-79 cells.
a Cells incubated for 48 h. b
Cells incubated for 120 h
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this could be one of the reasons of showing relatively
greater apoptosis in the case of cells treated with NPs.
3.9 cDNA microarray screening for potential gene
expression changes induced by etoposide loaded
in nanoparticles in cells
We have shown our interest to discover the potential gene
expression changes in Y-79 cells after treatment with NPs
mainly for two reasons. One reason is that the Y-79 cells
form tumours in the murine models that closely resemble
the naturally occurring tumuor in anatomic sites without
disrupting the choroids and sclera or involving the anterior
chamber (Chévez-Barrios et al. 2000). The second reason is
that RB tumours found in Indian RB patients are mostly
advanced tumours, presenting with choroidal and optic
nerve invasion (Moutushy et al. 2010). Therefore, the Y-79
cell line is appropriate for in vitro studies and the data can
be translated to actual tumour state. In order to screen and
compare the potential gene expressional changes occurring
in the Y-79 cells treated with (0.0005 μg/ml) of NPs and
with native etoposide, RNA was extracted from Y-79 cells
to perform cDNA microarray analysis.
3.10 Identification of genetic networks
through upregulation and downregulation
of various genes
Etoposide is one of the potential drugs that are currently
being used for retinoblastoma treatment. This is the first
report that demonstrated the delivery of etoposide drug in
nanoparticulate formulation to the retinoblastoma cells and
its modulation of gene activity. Our microarray analysis
revealed differential regulation of various genes which
played an active role towards cell apoptosis and oncogenesis.
The results of the cDNA microarray revealed the changed
expression of genes (upregulation of 171 genes, down-
regulation of 280 genes) in the retinoblastoma cell line
treated with etoposide nanoparticles and native etoposide;
however, the etoposide nanoparticles illustrated an enhanced
upregulated gene expression level and downregulated gene
expression level, depicted in the cluster diagram (Fig. 10a and
Electronic supplementary material (ESM) Tables S1 and S2).
Only genes with p≤0.05 and log ratio of at least 2.0 were
taken for upregulation, and a log ratio of 0.5 was considered
for downregulation. In both the biologic replicates, the
median log ratio of 1 was considered for expression analysis.
The microarray analysis demonstrated that NP treatment
primarily upregulated the expression of three groups of
potential genes related to cell cycle and cell differentiation,
cell migration, apoptosis and few anti-apoptosis-related
genes. Amongst them, seven genes are upregulated more
than onefold in apoptosis, such as Homo sapiens (BCL2-
antagonist of cell death (BAD), caspase 8, apoptosis-related
cysteine peptidase (CASP8; Polzien et al. 2009), growth arrest
and DNA damage-inducible, alpha (GADD45A), PERP,
TP53 apoptosis effector (PERP), tumour necrosis factor
TNF receptor-associated factor 1 (TRAF1; Kim et al. 2010),
caspase recruitment domain family, member 14 (CARD14)
and members of the tumour necrosis factor receptor super-
family (TNFRSF17, TNFRSF1B, TNFRSF10B, TNFRSF19;
Coffer et al. 1998). Two cell cycle and cell differentiation
genes, i.e. nuclear factor of kappa light polypeptide gene
enhancer in B cells inhibitor, alpha (NFKBIA, platelet-derived
growth factor alpha polypeptide (PDGFA), and two anti-
Fig. 9 a Annexin-V FITC staining for apoptosis. Y-79 cells were
treated with varying concentrations of drug in solution and in
nanoformulation for 5 days. The apoptotic response was determined
by Annexin-V FITC and PI staining procedure. b Analysis of DNA
fragmentation by agarose gel electrophoresis. i Y-79 cells treated with
native etoposide and NPs (0.0005 μg/ml) for 5 days. Control cells
(lane 1), native etoposide (lane 2), NPs (lane 3) and DNA marker
(lane 4). ii Y-79 cells treated with native etoposide (0.005 μg/ml) and
NPs (0.005 μg/ml) for 5 days. Control cells (lane 1), native etoposide
(lane 2), NPs (lane 3) and DNA marker (lane 4)
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apoptosis, i.e., baculoviral IAP repeat-containing 3 (BIRC3),
transcript variant 1, BCL2-related protein A1 (BCL2A1),
mRNAwere upregulated. Similarly, angiogenesis factor genes,
i.e. E74-like factor 3 (ets domain transcription factor, epithelial-
specific; ELF3) and Kruppel-like factor 2 (lung; KLF2), were
also upregulated. Moreover, one gene for cell proliferation, i.e.
v-fos FBJ murine osteosarcoma viral oncogene homolog
(FOS), and anti-proliferation, i.e. dual specificity phosphatase
1 (DUSP1), were upregulated too (details in ESM Tables S1
and S2). On the other hand, NP action also resulted in the
significant downregulation of genes (less than onefold) related
to cell cycle cell differentiation, cell invasion, various
oncogenes, migrations, proliferations, angiogenesis and DNA
repair, as depicted in ESM Tables S1 and S2.
3.11 Functional grouping of differentially expressed genes
All the distinct gene identifications were examined for their
known biologic function according to gene ontology
convention and grouped in their respective functional
category. The proportion of each functional category in
the total number of selected identified genes (taken as
100%) was shown in Fig. 10b. Amongst the upregulated
genes, the majority of genes belonged to the apoptosis
functional category (60%, i in Fig. 10b). Therefore, it
became interesting to speculate that drug delivery through
nanoparticulate formulation may promote apoptosis in Y-79
cells. However, other identified genes belonged to prolifer-
ation, anti-proliferation, angiogenesis, anti-angiogenesis
Fig. 10 a Display of microarray images of Y-79 cells treated with
(0.0005 μg/ml) of native etoposide and (0.0005 μg/ml) NPs.
Horizontal line represents the average expression of the individual
genes modified. Red and green indicate the increased and decreased
expression of genes. The figure represents one of the three replicates.
b Functional grouping of upregulated genes (i) and downregulated
genes (ii) in Y-79 cells treated with NPs. All the distinct gene
identification were examined for their known biologic functions
according to gene oncology convention and grouped in the respective
functional category. The proportion of each functional category in the
total number of selected identified genes (taken as 100%) is shown
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and anti-apoptotic genes. Amongst the downregulated
genes, one third of the total genes belonged to the
oncogenic functional category (47%) and other cell cycle
and differentiation groups (16%, ii in Fig. 10b). However,
other downregulated genes belonged to cellular invasion,
anti-apoptosis, proliferation, and angiogenic genes.
In particular, genes involved in oncogenic signalling and
apoptotic events were discussed below. Genes related to
apoptosis such as CARD14, associated with induction of
apoptosis via NFKB activation (Shammas et al. 2006);
TNFRSF10B, a member of the TNF-receptor superfamily
(Kim et al. 2010); p53 apoptosis effector related to PMP-22
(PERP), a transcriptional target gene of p53 tumour
suppressor (Davies et al. 2009); Gadd45a, a p53 effector
and stress-inducible gene, like p53 (Hildesheim et al.
2002); and BAD, a pro-apoptotic member of the Bcl-2
protein family (Polzien et al. 2009), have been significantly
upregulated in cells treated with etoposide. These changes
were coupled with the downregulation of important
oncogenes such as KIF14, FGR, AKT3, MYB and MET.
The mitotic kinesin gene KIF14 has been predicted to be
one of the possible oncogenes in the 1q region which was
found to overexpress by more than two orders of magnitude
in RB (Corson et al. 2005). Another proto-oncogene, FGR,
is expressed in elevated level in invasive breast cancer and
seems to have a negative impact on disease-specific
survival (Mayer and Krop 2010). AKT3 serine/threonine
protein kinase that has been implicated in mediating a
variety of biological responses, which include inhibition of
apoptosis and stimulation of cellular growth (Coffer et al.
1998), is the predominantly active family member of AKT.
The increased AKT3 gene copy number and/or loss of a
negative regulatory phosphatase called PTEN leads to
AKT3 activation, which reduces melanoma cell apoptosis
mediated through caspase-3 to promote melanoma devel-
opment (Stahl et al. 2004). MYB overexpressed in colon
cancer upregulates Bcl-xL and increases tumorigenesis of
colon carcinoma cells by inhibiting the apoptotic process
(Biroccio et al. 2001). MET hepatocyte growth factor
contributes to oncogenesis and tumour progression in
several human cancers and promotes aggressive cellular
invasiveness that is strongly linked to tumour metastasis
(Giubellino et al. 2009). Few genes leads to tumour
proliferation, such as BCL2, BCL11A; cell migration
MMP8, CD44 and drug resistance ABCA1, ABCC4,
ABCC1, ABCA5 were also found to be significantly
downregulated in response to treatment. BCL11A defines
a superfamily of C2HC zinc-finger transcription factors
involved in hematopoietic malignancies (Liu et al. 2006).
Bcl-2 is the prominent member of a family of proteins that
are responsible for dysregulation of apoptosis and preven-
tion of death in cancer cells (Gross et al. 1999). The ABC
transporters investigated might act as drug transporters and
resistance (ABCA1, ABCA5, ABCC1 and ABCC4; Gillet
et al. 2004).
Our functional study showed induced apoptotic event
and reduced cell proliferation, and microarray analysis
revealed a wide network of etoposide responsive genes
which are involved in initiating apoptosis and reducing
tumour oncogenesis. This might be due to the more uptake
of etoposide into cells through endocytosis via nano-
particles. Thus, NPs can persuade more apoptosis due to
the accumulation of more drug as compared to the native
etoposide inside the cell.
4 Conclusions
We report for the first time that drug-loaded nanoparticles
affect effectively the genetic network of cancer cells, leading
to enhanced apoptosis. In the current study, we have
successfully prepared etoposide-loaded nanoparticles with
higher entrapment efficiency, ~86% with an optimum size
range. These etoposide-loaded nanoparticles displayed greater
cellular drug uptake, sustained drug retention and an enhanced
anti-proliferative effect of the encapsulated anti-neoplastic
agent in Y-79 cancer cells. Furthermore, microarray analysis
exemplifies that these drug-loaded nanoparticles could rapidly
induce cell cycle disturbance by inhibiting the expression of
multiple cell cycle regulatory genes and upregulating
apoptotic-related genes. Thus, at present, these drug-loaded
nanoparticles could focus their therapeutic strategy towards
toxicity to tumour cells, but not to healthy normal cells, in a
dose-limiting manner. Hence, this nanoparticulate formulation
could be a more effective promising approach for expanding
tumour-targeted cancer therapy.
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